HIV Prevention and Care

2

Review clinical trials related to HIV Prevention and Care. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea

This study tests a mobile application (app) designed to support sexual health and prevent human immunodeficiency virus (HIV) among young men in South Korea. Researchers are interested to learn if the app is acceptable, easy to use, and helpful for young men who have sex with men (MSM). Participants will complete a 15-minute online survey at the start of the study and another 15-minute survey 3 months later. Participants will be randomly assigned to 1 of 2 study groups for 3 months: 1. Intervention Group: Participants receive access to the full mobile app, called Bandi. The app includes health articles, quizzes, community discussion forums, a personal sexual health log, and a clinic finder. 2. Control Group: Participants receive access to a basic version of the app that includes informational articles and the clinic finder only. Researchers will compare both groups over 3 months to see if using the full app leads to higher rates of HIV testing and lower sexual risk behaviors.

Participants needed: 50
Trial details
Age: 18-35Biological sex: MaleType: InterventionalSponsor: Seul Ki ChoiUpdated: Aug 3, 2026Locations: 1
Eligibility criteria

Male sex assigned at birth and current male gender identity [+6]

Assigned female at birth or do not currently identify as male [+6]

Status: Recruiting

Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP

The purpose of this project is to test a culturally-tailored, community-delivered long-acting injectable PrEP (lenacapavir) program for Latine gay and bisexual men (GBM) and transgender women (TGW). The objective is to evaluate whether this intervention demonstrates greater persistence on lenacapavir for Latine GBM and TGW compared with what has been observed historically at the Duke PrEP Clinic.

Participants needed: 100
Trial details
Phase: Phase 4Age: 18+Biological sex: MaleType: InterventionalSponsor: Duke UniversityUpdated: Feb 2, 2026Locations: 1
Eligibility criteria

Participants must be assigned male sex at birth. [+6]

Individuals living with HIV. [+4]